
    
      This is a phase I trial to determine the safety and tolerability of the combination of
      obinutuzumab, lenalidomide, and HDMP for patients with RS. There is not a standard of care
      for patients with Richter's Syndrome (RS). Ten patients will be enrolled with RS diagnosed by
      histology or flow cytometry and CLL, regardless of prior treatment for either condition.
    
  